Mitochondrial DNA Methylation as a Predictor of Immunotherapy Outcomes and Prognosis in Lung Adenocarcinoma: Insights from Single-Cell RNA Sequencing and Machine Learning Approaches - Top-Institutions - MDSpire

Mitochondrial DNA Methylation as a Predictor of Immunotherapy Outcomes and Prognosis in Lung Adenocarcinoma: Insights from Single-Cell RNA Sequencing and Machine Learning Approaches

  • By

  • Jian Ding

  • Gang Cheng

  • Qian Xue

  • Weizhen Guo

  • Yikun Cheng

  • Cheng Yang

  • Jiabing Tong

  • Zegeng Li

  • Yating Gao

  • February 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Lung Cancer
    • Cancer Genomics
    • Immunotherapy
    • Mitochondrial Biology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Oncology
    • Cancer Epigenetics
    • Computational Biology
    • Mitochondrial Research

  • #3

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Lung Cancer
    • Epigenetics
    • Immunotherapy
    • Single-Cell Genomics

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Cancer Biology
    • Mitochondrial Epigenetics
    • Lung Cancer
    • Bioinformatics

  • #5

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Cancer Genomics
    • Immunotherapy
    • Single-Cell Technologies
    • Mitochondrial Biology

Original Source(s)

Mitochondrial DNA Methylation as a Predictor of Immunotherapy Outcomes and Prognosis in Lung Adenocarcinoma: Insights from Single-Cell RNA Sequencing and Machine Learning Approaches

  • by Jian Ding, Gang Cheng, Qian Xue, Weizhen Guo, Yikun Cheng, Cheng Yang, Jiabing Tong, Zegeng Li, Yating Gao

  • February 10, 2026

Related Content

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP